|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, December 28, 2011 ) Chicago, Illinois - The Stockfather (www.thestockfather.com) believes that Tengion Inc. (NasdaqGM: TNGN) will continue to move upwards, after being beaten down all the way to .33 cents a share.
Tengion, Inc. (TNGN) has a top notch pipeline, and a great management and medical team.
Tengion, Inc. (TNGN) could turn out like Keryx Biopharmaceuticals Inc. (NasdaqCM: KERX), which traded in the similar range as (TNGN) is trading now, before taking off and hitting nearly $7 a share.
Like Keryx Biopharmaceuticals Inc. (KERX), Tengion, Inc. (TNGN) also has an attractive attractive looking pipeline, with potentially lucrative product candidates.
Tengion is developing products from a patient's own cells that harness the body's ability to regenerate native-like tissues and organs.
Many out there do not believe in stem cells being taken from fetuses, we at Thestockfather.com are also in that category, that is another reason why we like Tengion (TNGN), because they use a patients own cells.
One of their potential blockbusters is their Tengion Neo-Urinary Conduit. To find out more about it, watch the video here: http://www.tengion.com/news/video1-small.cfm
Shares of (TNGN) appear to have bottomed out, most importantly, they seem to be an extreme bargain at the current price of .40 cents per share.
Thestockfather.com feels that (TNGN) will go down as one of their most Mega Stock Picks.
Dendreon Corporation (NasdaqGS: DNDN) is currently trading $36.38 lower than its 52 week high.,
Dendreon Corporation (DNDN) is now trading at $7.58, but with their PROVENGE drug and their other candidates, (DNDN) could be trading back over $20 in 2012.
Human Genome Sciences, Inc. (NasdaqGS: HGSI) is currently trading at $7.07, which is close to its 52 week low.
Human Genome Sciences Inc. (HGSI) has an outstanding pipeline, and could be trading over $20 in 2012.
Keryx Biopharmaceuticals, Inc. (NasdaqCM: KERX), is another biotech stock trading near its 52 week low.
Keryx Biopharmaceuticals Inc. (KERX) has a smaller pipeline than (TNGN) and (HGSI), but both of their drug candidates are currently in phase III studies.
Zalicus Inc. (NasdaqGM: ZLCS) is currently trading at $1.20, and has a 52 week high of $3.21.
Like (TNGN) and (HGSI), Zalicus Inc. (ZLCS) has a very busy and attractive pipeline.
Tengion Inc. (TNGN) has a 52 week high of over $6, so (TNGN) is ready for a big bounce, but that isn't what makes (TNGN) exciting, it is their technology and pipeline.
Regenerative medicine is the future, and investors can currently get in dirt cheap at .40 cents per share. This is why Thestockfather.com rates (TNGN) a "Strong Buy".
About The Stockfather:
The Stockfather searches the markets (from OTC to NYSE) for stocks positioned to make big gains. Stocks and companies are featured on The Stockfather web site and e-newsletter.
Disclaimer:
For this news release, The Stockfather was not paid to profile the company(ies) or stock(s) mentioned. The Stockfather does not own any shares of the stock(s) mentioned. The Stockfather is not a registered investment advisor. Investors are responsible for doing their own research and obtaining professional investment advice. Investors should visit www.thestockfather.com for further disclosure information.
Mega Stock Picks
Editor
312-473-5916
info@megastockpicks.com 
Source: EmailWire.com
|
|
|
|
